InterCure Estimates NIS265M 2025 Revenue, 11% Growth and NIS43M Cash
InterCure estimates full-year 2025 revenue of NIS 265 million, an 11% increase over 2024, with second-half revenue nearly 20% higher than the prior-year period. The company posted its twelfth consecutive positive Adjusted EBITDA, held NIS 43 million in cash at year-end, and generated its first significant revenues from the German market.
1. Preliminary Financial Results
InterCure estimates full-year 2025 revenue at NIS 265 million, up 11% from 2024, with second-half revenue of approximately NIS 135 million representing nearly 20% year-over-year growth. The company ended the year with NIS 43 million in cash on hand as of December 31, 2025.
2. Adjusted EBITDA Streak
The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA in both H1 and H2 2025, reflecting disciplined cost management and robust margin performance.
3. Market Expansion and Partnerships
InterCure recorded its first significant revenues from the German market during H2 2025 and launched over 70 new GMP-certified SKUs. Strategic agreements include a share purchase to acquire Botanico Ltd.—expected to generate over NIS 30 million in H2 2026 revenues—and a 28% stake in Cannasoul R&D Ltd. to bolster research and pharmaceutical capabilities.
4. War Damages Compensation and Facility Resumption
The company resumed production, importation and sales from its Nir Oz facility, delivering first batches since the October 7, 2023 attack, and secured NIS 81 million in advance compensation toward a NIS 251 million war-related damage claim.